Viewing Study NCT05057494

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:31 AM
Ignite Modification Date: 2026-02-09 @ 7:48 AM
Study NCT ID: NCT05057494
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-17
First Post: 2021-09-16
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Chronic lymphocytic leukemia View
None Small lymphocytic lymphoma View
None Acalabrutinib View
None Venetoclax View
None Obinutuzumab View
None B-cell lymphoma 2 inhibitors View